Related Experiment Videos
p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis
1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, TX 77030, USA.
Abstract:
HER2/neu, a receptor tyrosine kinase oncogene, promotes mitogenic growth and transformation of cancer cells. We previously identified that its oncogenic signals down-regulate the cyclin-dependent kinase inhibitor p27 Kip1, which is defined as a haplo-insufficient tumor suppressor. Here, we applied the human p27 gene as a novel anticancer agent for HER2/neu-overexpressing cells under the control of a tetracycline (tet)-regulated gene expression system. Overexpression of p27 inhibits HER2/neu-activated CDK2 activity, cell proliferation, and transformation. Most significantly for clinical application, p27 expression in HER2/neu-overexpressing cells can be regulated in vivo and reduce the tumor volume in a tumor model. The findings demonstrate the applicability of employing p27 in HER2/neu-associated cancer gene therapy.
Insights
Gene therapy using p27 shows promise for HER2/neu-overexpressing cancers. Introducing the p27 gene inhibits cancer cell growth and reduces tumor volume in vivo, offering a potential new treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- HER2/neu oncogene drives cancer cell growth and transformation.
- HER2/neu signaling down-regulates the tumor suppressor p27 Kip1.
- p27 Kip1 acts as a haplo-insufficient tumor suppressor.
Purpose of the Study:
- To investigate the therapeutic potential of the human p27 gene in HER2/neu-overexpressing cancer cells.
- To evaluate the efficacy of a tetracycline-regulated gene expression system for p27 delivery.
- To assess the in vivo impact of p27 overexpression on tumor growth.
Main Methods:
- Utilized a tetracycline-regulated gene expression system to control p27 gene delivery.
- Overexpressed p27 in HER2/neu-overexpressing cancer cells.
- Assessed inhibition of CDK2 activity, cell proliferation, and transformation.
- Evaluated p27 expression and tumor volume in an in vivo tumor model.
Main Results:
- p27 overexpression effectively inhibited HER2/neu-activated CDK2 activity.
- Cell proliferation and transformation were significantly reduced by p27.
- p27 expression was successfully regulated in vivo.
- Tumor volume was reduced in the established tumor model.
Conclusions:
- The human p27 gene can serve as a novel anticancer agent for HER2/neu-associated cancers.
- p27 gene therapy demonstrates efficacy in inhibiting cancer progression and reducing tumor burden.
- Findings support the clinical applicability of p27-based gene therapy for HER2/neu-overexpressing tumors.